FDA Places Partial Clinical Hold on MacroGenics' Phase 2 LINNET Study Following Patient Death

summarizeSummary

The FDA has placed a partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab due to serious safety events, including a patient death, halting new patient enrollment.

check_boxKey Events

• Partial Clinical Hold Issued

  The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the Phase 2 LINNET study of lorigerlimab.

• Enrollment Halted

  No new patients will be enrolled in the LINNET study until the partial hold is lifted by the FDA, though current participants may continue to receive the study drug.

• Serious Safety Events Reported

  The hold was initiated following the company's notification of a temporary pause in enrollment due to recent safety events, including Grade 4 thrombocytopenia (N=2), Grade 4 myocarditis (N=1), and Grade 4 neutropenia with concurrent septic shock (N=1), which led to a Grade 5 (fatal) event.

• Impact on Pipeline

  This setback significantly impacts the development timeline and future prospects for lorigerlimab, an investigational bispecific DART® molecule targeting PD-1 and CTLA-4 for gynecologic cancers.

auto_awesomeAnalysis

The FDA's partial clinical hold on the Phase 2 LINNET study for lorigerlimab is a significant negative development for MacroGenics. The halt in new patient enrollment, triggered by serious safety events including a Grade 5 (fatal) event, directly impacts the development timeline and commercial prospects of this investigational bispecific molecule. For a clinical-stage biopharmaceutical company, a setback of this magnitude in a mid-stage trial can severely undermine investor confidence and necessitate a re-evaluation of the drug candidate's viability and the company's pipeline strategy. Investors should monitor updates regarding the resolution of the clinical hold and any potential changes to the study protocol or future development plans.